Published in Clin Dev Immunol on July 15, 2013
RNA Sequence Analysis of Human Huntington Disease Brain Reveals an Extensive Increase in Inflammatory and Developmental Gene Expression. PLoS One (2015) 1.59
Inflammation in neurodegenerative diseases--an update. Immunology (2014) 1.30
Microglial M1/M2 polarization and metabolic states. Br J Pharmacol (2015) 1.14
The role of the immune system in triplet repeat expansion diseases. Mediators Inflamm (2015) 0.85
Mutant Huntingtin Does Not Affect the Intrinsic Phenotype of Human Huntington's Disease T Lymphocytes. PLoS One (2015) 0.79
Immune and neurotrophin stimulation by electroconvulsive therapy: is some inflammation needed after all? Transl Psychiatry (2015) 0.79
RNA-Seq of Huntington's disease patient myeloid cells reveals innate transcriptional dysregulation associated with proinflammatory pathway activation. Hum Mol Genet (2016) 0.79
Changing the face of kynurenines and neurotoxicity: therapeutic considerations. Int J Mol Sci (2015) 0.78
Laquinimod dampens hyperactive cytokine production in Huntington's disease patient myeloid cells. J Neurochem (2016) 0.77
The Potential Regulatory Mechanisms of miR-196a in Huntington's Disease through Bioinformatic Analyses. PLoS One (2015) 0.76
Pyruvate blocks blood-brain barrier disruption, lymphocyte infiltration and immune response in excitotoxic brain injury. Am J Neurodegener Dis (2016) 0.76
The Effects of Pharmacological Inhibition of Histone Deacetylase 3 (HDAC3) in Huntington's Disease Mice. PLoS One (2016) 0.75
Neural and mesenchymal stem cells in animal models of Huntington's disease: past experiences and future challenges. Stem Cell Res Ther (2015) 0.75
Safety of Striatal Infusion of siRNA in a Transgenic Huntington's Disease Mouse Model. J Huntingtons Dis (2015) 0.75
Transgenic rat model of Huntington's disease: a histopathological study and correlations with neurodegenerative process in the brain of HD patients. Biomed Res Int (2014) 0.75
PIAS1 Regulates Mutant Huntingtin Accumulation and Huntington's Disease-Associated Phenotypes In Vivo. Neuron (2016) 0.75
Identification and functional analysis of the BIM interactome; new clues on its possible involvement in Epstein-Barr Virus-associated diseases. J Biol Res (Thessalon) (2015) 0.75
Autophagy and Microglia: Novel Partners in Neurodegeneration and Aging. Int J Mol Sci (2017) 0.75
Beneficial effect of rice bran extract against 3-nitropropionic acid induced experimental Huntington's disease in rats. Toxicol Rep (2015) 0.75
Alterations in mRNA 3' UTR Isoform Abundance Accompany Gene Expression Changes in Human Huntington's Disease Brains. Cell Rep (2017) 0.75
Beneficial effects of glatiramer acetate in Huntington's disease mouse models: evidence for BDNF-elevating and immunomodulatory mechanisms. Brain Res (2017) 0.75
Dendritic cells and the control of immunity. Nature (1998) 56.54
Development of monocytes, macrophages, and dendritic cells. Science (2010) 12.86
Exon 1 of the HD gene with an expanded CAG repeat is sufficient to cause a progressive neurological phenotype in transgenic mice. Cell (1996) 12.59
Alternative activation of macrophages: an immunologic functional perspective. Annu Rev Immunol (2009) 11.63
Dendritic cells: specialized and regulated antigen processing machines. Cell (2001) 10.44
Control of microglial neurotoxicity by the fractalkine receptor. Nat Neurosci (2006) 8.25
Impaired monocyte migration and reduced type 1 (Th1) cytokine responses in C-C chemokine receptor 2 knockout mice. J Clin Invest (1997) 7.58
Microglial physiology: unique stimuli, specialized responses. Annu Rev Immunol (2009) 6.79
M-1/M-2 macrophages and the Th1/Th2 paradigm. J Immunol (2000) 6.61
In vivo analysis of dendritic cell development and homeostasis. Science (2009) 6.42
The relationship between trinucleotide (CAG) repeat length and clinical features of Huntington's disease. Nat Genet (1993) 5.82
Relationship between trinucleotide repeat expansion and phenotypic variation in Huntington's disease. Nat Genet (1993) 5.70
The enigmatic plasmacytoid T cells develop into dendritic cells with interleukin (IL)-3 and CD40-ligand. J Exp Med (1997) 5.23
Neuroinflammation in Parkinson's disease: a target for neuroprotection? Lancet Neurol (2009) 4.88
The receptor tyrosine kinase Flt3 is required for dendritic cell development in peripheral lymphoid tissues. Nat Immunol (2008) 4.86
A Nurr1/CoREST pathway in microglia and astrocytes protects dopaminergic neurons from inflammation-induced death. Cell (2009) 4.60
Defects in macrophage recruitment and host defense in mice lacking the CCR2 chemokine receptor. J Exp Med (1997) 4.57
Microglia as a source and target of cytokines. Glia (2002) 4.48
Selective striatal neuronal loss in a YAC128 mouse model of Huntington disease. Hum Mol Genet (2003) 4.07
Structures of complement component C3 provide insights into the function and evolution of immunity. Nature (2005) 4.01
Neurological abnormalities in a knock-in mouse model of Huntington's disease. Hum Mol Genet (2001) 3.84
Full-length human mutant huntingtin with a stable polyglutamine repeat can elicit progressive and selective neuropathogenesis in BACHD mice. J Neurosci (2008) 3.54
Broad expression of Toll-like receptors in the human central nervous system. J Neuropathol Exp Neurol (2002) 3.53
A YAC mouse model for Huntington's disease with full-length mutant huntingtin, cytoplasmic toxicity, and selective striatal neurodegeneration. Neuron (1999) 3.50
Human blood contains two subsets of dendritic cells, one immunologically mature and the other immature. Immunology (1994) 3.46
Fumaric acid esters exert neuroprotective effects in neuroinflammation via activation of the Nrf2 antioxidant pathway. Brain (2011) 3.38
Specific coupling of NMDA receptor activation to nitric oxide neurotoxicity by PSD-95 protein. Science (1999) 3.23
Microglia as neuroprotective, immunocompetent cells of the CNS. Glia (2002) 3.12
Time course of early motor and neuropathological anomalies in a knock-in mouse model of Huntington's disease with 140 CAG repeats. J Comp Neurol (2003) 3.08
Glial cells as intrinsic components of non-cell-autonomous neurodegenerative disease. Nat Neurosci (2007) 3.02
Inhibition of caspase-1 slows disease progression in a mouse model of Huntington's disease. Nature (1999) 2.97
Huntingtin-protein interactions and the pathogenesis of Huntington's disease. Trends Genet (2004) 2.88
Glutamate receptors, neurotoxicity and neurodegeneration. Pflugers Arch (2010) 2.83
A novel pathogenic pathway of immune activation detectable before clinical onset in Huntington's disease. J Exp Med (2008) 2.78
Normal huntingtin function: an alternative approach to Huntington's disease. Nat Rev Neurosci (2005) 2.78
Innate immunity in the central nervous system. J Clin Invest (2012) 2.77
Expression of mutant huntingtin in glial cells contributes to neuronal excitotoxicity. J Cell Biol (2005) 2.57
Interleukin-4- and interleukin-13-mediated alternatively activated macrophages: roles in homeostasis and disease. Annu Rev Immunol (2013) 2.47
Inflammatory neurodegeneration and mechanisms of microglial killing of neurons. Mol Neurobiol (2010) 2.43
Cellular localization of the Huntington's disease protein and discrimination of the normal and mutated form. Nat Genet (1995) 2.33
Toll-like receptors in neurodegeneration. Brain Res Rev (2008) 2.15
From calcium signaling to cell death: two conformations for the mitochondrial permeability transition pore. Switching from low- to high-conductance state. Biochim Biophys Acta (1998) 2.07
Chronology of behavioral symptoms and neuropathological sequela in R6/2 Huntington's disease transgenic mice. J Comp Neurol (2005) 1.95
Microglial activation in presymptomatic Huntington's disease gene carriers. Brain (2007) 1.93
Microglial activation correlates with severity in Huntington disease: a clinical and PET study. Neurology (2006) 1.88
Role of complement in neurodegeneration and neuroinflammation. Mol Immunol (2006) 1.73
Creatine in Huntington disease is safe, tolerable, bioavailable in brain and reduces serum 8OH2'dG. Neurology (2006) 1.73
Huntington's disease: seeing the pathogenic process through a genetic lens. Trends Biochem Sci (2006) 1.72
Glutamate becomes neurotoxic via the N-methyl-D-aspartate receptor when intracellular energy levels are reduced. Brain Res (1988) 1.71
Huntington's disease gene (IT15) is widely expressed in human and rat tissues. Neuron (1993) 1.69
Activation of the IkappaB kinase complex and nuclear factor-kappaB contributes to mutant huntingtin neurotoxicity. J Neurosci (2004) 1.64
Fumaric acid esters are effective in chronic experimental autoimmune encephalomyelitis and suppress macrophage infiltration. Clin Exp Immunol (2006) 1.62
Minocycline in Huntington's disease: a pilot study. Mov Disord (2004) 1.59
Mutant huntingtin and mitochondrial dysfunction. Trends Neurosci (2008) 1.59
Proteomic profiling of plasma in Huntington's disease reveals neuroinflammatory activation and biomarker candidates. J Proteome Res (2007) 1.59
Microglia. Metab Brain Dis (2004) 1.58
Complement components of the innate immune system in health and disease in the CNS. Immunopharmacology (2000) 1.56
Polyglutamine-expanded huntingtin promotes sensitization of N-methyl-D-aspartate receptors via post-synaptic density 95. J Biol Chem (2001) 1.50
Reduction of human monocytic cell neurotoxicity and cytokine secretion by ligands of the cannabinoid-type CB2 receptor. Br J Pharmacol (2003) 1.47
Ferritin accumulation in dystrophic microglia is an early event in the development of Huntington's disease. Glia (2007) 1.40
Selective degeneration and nuclear localization of mutant huntingtin in the YAC128 mouse model of Huntington disease. Hum Mol Genet (2005) 1.40
The role of inflammasome-derived IL-1 in driving IL-17 responses. J Leukoc Biol (2012) 1.37
Mitochondrial impairment in patients and asymptomatic mutation carriers of Huntington's disease. Mov Disord (2005) 1.33
Increased complement biosynthesis by microglia and complement activation on neurons in Huntington's disease. Exp Neurol (1999) 1.32
CB2 cannabinoid receptor agonists attenuate TNF-alpha-induced human vascular smooth muscle cell proliferation and migration. Br J Pharmacol (2007) 1.32
Penetration of interleukin-6 across the murine blood-brain barrier. Neurosci Lett (1994) 1.32
Interleukin 6 receptor blockade in patients with neuromyelitis optica nonresponsive to anti-CD20 therapy. JAMA Neurol (2013) 1.30
Mutant huntingtin in glial cells exacerbates neurological symptoms of Huntington disease mice. J Biol Chem (2010) 1.25
Distinct neuroinflammatory profile in post-mortem human Huntington's disease. Neuroreport (2009) 1.23
Inflammation in the early stages of neurodegenerative pathology. J Neuroimmunol (2011) 1.21
Dramatic shifts in circulating CD4 but not CD8 T cell subsets in mild Alzheimer's disease. J Alzheimers Dis (2009) 1.20
Mitochondrial dysfunction and oxidative stress activate inflammasomes: impact on the aging process and age-related diseases. Cell Mol Life Sci (2012) 1.19
Neuroinflammation in Huntington's disease. J Neural Transm (Vienna) (2010) 1.16
Efficient T-cell surveillance of the CNS requires expression of the CXC chemokine receptor 3. J Neurosci (2004) 1.13
Abnormal peripheral chemokine profile in Huntington's disease. PLoS Curr (2011) 1.12
Imaging microglial activation in Huntington's disease. Brain Res Bull (2006) 1.12
Mutant huntingtin impairs immune cell migration in Huntington disease. J Clin Invest (2012) 1.11
Neuroinflammation and microglia: considerations and approaches for neurotoxicity assessment. Expert Opin Drug Metab Toxicol (2008) 1.11
Efficacy of fumaric acid esters in the R6/2 and YAC128 models of Huntington's disease. PLoS One (2011) 1.10
Acute brain injury triggers MyD88-dependent, TLR2/4-independent inflammatory responses. Am J Pathol (2007) 1.03
Boosting T-cell immunity as a therapeutic approach for neurodegenerative conditions: the role of innate immunity. Neuroscience (2008) 1.02
Mitochondrial dynamics and their impact on T cell function. Cell Calcium (2012) 1.01
The complement system in central nervous system diseases. Autoimmunity (2006) 1.00
Cannabinoid receptor 2 signaling in peripheral immune cells modulates disease onset and severity in mouse models of Huntington's disease. J Neurosci (2012) 1.00
Severe ultrastructural mitochondrial changes in lymphoblasts homozygous for Huntington disease mutation. Mech Ageing Dev (2005) 1.00
The inflammatory response in Alzheimer's disease. J Periodontol (2008) 0.97
Proinflammatory cytokines and apoptosis following glutamate-induced excitotoxicity mediated by p38 MAPK in the hippocampus of neonatal rats. J Neuroimmunol (2005) 0.96
Huntington's disease and its therapeutic target genes: a global functional profile based on the HD Research Crossroads database. BMC Neurol (2012) 0.96
Electroacupuncture reduces the expression of proinflammatory cytokines in inflamed skin tissues through activation of cannabinoid CB2 receptors. Eur J Pain (2011) 0.95
Drug targeting of erythropoietin across the primate blood-brain barrier with an IgG molecular Trojan horse. J Pharmacol Exp Ther (2010) 0.95
Alpha2-macroglobulin attenuates beta-amyloid peptide 1-40 fibril formation and associated neurotoxicity of cultured fetal rat cortical neurons. J Neurochem (1998) 0.93
Neuroprotection with a brain-penetrating biologic tumor necrosis factor inhibitor. J Pharmacol Exp Ther (2011) 0.92
Enhanced Th17-cell responses render CCR2-deficient mice more susceptible for autoimmune arthritis. PLoS One (2011) 0.91
The role of immunity in Huntington's disease. Mol Psychiatry (2011) 0.89
Cell surface changes in the Candida albicans mitochondrial mutant goa1Δ are associated with reduced recognition by innate immune cells. Cell Microbiol (2013) 0.88
Anti-inflammatory treatment with acetylsalicylate or rofecoxib is not neuroprotective in Huntington's disease transgenic mice. Neurobiol Dis (2004) 0.88
Brain plasticity and microglia: is transsynaptic glial activation in the thalamus after limb denervation linked to cortical plasticity and central sensitisation? J Physiol Paris (2002) 0.87
Hepatic mitochondrial dysfunction in manifest and premanifest Huntington disease. Neurology (2013) 0.86
PGC-1alpha downstream transcription factors NRF-1 and TFAM are genetic modifiers of Huntington disease. Mol Neurodegener (2011) 0.84
Sodium chloride drives autoimmune disease by the induction of pathogenic TH17 cells. Nature (2013) 4.57
Contrasting disease patterns in seropositive and seronegative neuromyelitis optica: A multicentre study of 175 patients. J Neuroinflammation (2012) 3.12
Failure of natalizumab to prevent relapses in neuromyelitis optica. Arch Neurol (2012) 2.12
Role of "Western diet" in inflammatory autoimmune diseases. Curr Allergy Asthma Rep (2014) 1.79
Pridopidine for the treatment of motor function in patients with Huntington's disease (MermaiHD): a phase 3, randomised, double-blind, placebo-controlled trial. Lancet Neurol (2011) 1.62
Role of the renin-angiotensin system in autoimmune inflammation of the central nervous system. Proc Natl Acad Sci U S A (2009) 1.56
Faster perceptual learning through excitotoxic neurodegeneration. Curr Biol (2012) 1.46
NR2A and NR2B receptor gene variations modify age at onset in Huntington disease. Neurogenetics (2004) 1.31
High salt reduces the activation of IL-4- and IL-13-stimulated macrophages. J Clin Invest (2015) 1.30
PGC-1alpha as modifier of onset age in Huntington disease. Mol Neurodegener (2009) 1.22
Pattern of axonal injury in murine myelin oligodendrocyte glycoprotein induced experimental autoimmune encephalomyelitis: implications for multiple sclerosis. Neurobiol Dis (2008) 1.20
Modulation of autoimmune demyelination by laquinimod via induction of brain-derived neurotrophic factor. Am J Pathol (2011) 1.17
Mitochondrial haplogroup H correlates with ATP levels and age at onset in Huntington disease. J Mol Med (Berl) (2010) 1.13
NR2A and NR2B receptor gene variations modify age at onset in Huntington disease in a sex-specific manner. Hum Genet (2007) 1.13
Glatiramer acetate treatment normalizes deregulated microRNA expression in relapsing remitting multiple sclerosis. PLoS One (2011) 1.10
Efficacy of fumaric acid esters in the R6/2 and YAC128 models of Huntington's disease. PLoS One (2011) 1.10
Astrocytes are less efficient in the removal of apoptotic lymphocytes than microglia cells: implications for the role of glial cells in the inflamed central nervous system. J Neuropathol Exp Neurol (2002) 1.02
Mechanisms of oxidative damage in multiple sclerosis and neurodegenerative diseases: therapeutic modulation via fumaric acid esters. Int J Mol Sci (2012) 1.02
What is influencing the phenotype of the common homozygous polymerase-γ mutation p.Ala467Thr? Brain (2012) 1.01
Response inhibition subprocesses and dopaminergic pathways: basal ganglia disease effects. Neuropsychologia (2009) 1.01
ASK1 and MAP2K6 as modifiers of age at onset in Huntington's disease. J Mol Med (Berl) (2008) 1.01
Severe ultrastructural mitochondrial changes in lymphoblasts homozygous for Huntington disease mutation. Mech Ageing Dev (2005) 1.00
Huntington's disease as caused by 34 CAG repeats. Mov Disord (2008) 0.99
Cyclooxygenase-2 is a neuronal target gene of NF-kappaB. BMC Mol Biol (2002) 0.97
Subcutaneous immunoglobulin infusion: a new therapeutic option in chronic inflammatory demyelinating polyneuropathy. Muscle Nerve (2008) 0.97
Successful management of natalizumab-associated progressive multifocal leukoencephalopathy and immune reconstitution syndrome in a patient with multiple sclerosis. Arch Neurol (2010) 0.96
Mechanisms mediating parallel action monitoring in fronto-striatal circuits. Neuroimage (2012) 0.95
Chorein-sensitive polymerization of cortical actin and suicidal cell death in chorea-acanthocytosis. FASEB J (2012) 0.93
Levels of error processing in Huntington's disease: a combined study using event-related potentials and voxel-based morphometry. Hum Brain Mapp (2008) 0.93
Time processing in Huntington's disease: a group-control study. PLoS One (2007) 0.93
Magnetic resonance perfusion imaging of resting-state cerebral blood flow in preclinical Huntington's disease. J Cereb Blood Flow Metab (2011) 0.92
Error processing in Huntington's disease. PLoS One (2006) 0.92
Functional compensation or pathology in cortico-subcortical interactions in preclinical Huntington's disease? Neuropsychologia (2007) 0.91
Assessment of simple movements and progression of Huntington's disease. J Neurol Neurosurg Psychiatry (2007) 0.91
Age at onset in Huntington's disease: replication study on the associations of ADORA2A, HAP1 and OGG1. Neurogenetics (2010) 0.90
Response inhibition in Huntington's disease-a study using ERPs and sLORETA. Neuropsychologia (2007) 0.90
On the role of fronto-striatal neural synchronization processes for response inhibition--evidence from ERP phase-synchronization analyses in pre-manifest Huntington's disease gene mutation carriers. Neuropsychologia (2011) 0.90
Pain in experimental autoimmune encephalitis: a comparative study between different mouse models. J Neuroinflammation (2012) 0.89
Sensitive particle acoustic quantification (SPAQ): a new ultrasound-based approach for the quantification of ultrasound contrast media in high concentrations. Invest Radiol (2005) 0.89
Effects of fumaric acid esters on blood-brain barrier tight junction proteins. Neurosci Lett (2013) 0.89
Action selection in a possible model of striatal medium spiny neuron dysfunction: behavioral and EEG data in a patient with benign hereditary chorea. Brain Struct Funct (2013) 0.88
Brain activation and functional connectivity in premanifest Huntington's disease during states of intrinsic and phasic alertness. Hum Brain Mapp (2011) 0.88
Default-mode network changes in preclinical Huntington's disease. Exp Neurol (2012) 0.88
NMDA receptor gene variations as modifiers in Huntington disease: a replication study. PLoS Curr (2011) 0.87
Brain-derived neurotrophic factor in neuroimmunology: lessons learned from multiple sclerosis patients and experimental autoimmune encephalomyelitis models. Arch Immunol Ther Exp (Warsz) (2013) 0.87
Altered ventral striatal activation during reward and punishment processing in premanifest Huntington's disease: a functional magnetic resonance study. Exp Neurol (2012) 0.87
Mutations in TITF1 are not relevant to sporadic and familial chorea of unknown cause. Mov Disord (2006) 0.87
Inflammation modulates anxiety in an animal model of multiple sclerosis. Behav Brain Res (2011) 0.87
Impaired motor speech performance in Huntington's disease. J Neural Transm (Vienna) (2013) 0.87
Upper gastrointestinal findings in Huntington's disease: patients suffer but do not complain. J Neural Transm (Vienna) (2009) 0.86
Increased cognitive functioning in symptomatic Huntington's disease as revealed by behavioral and event-related potential indices of auditory sensory memory and attention. J Neurosci (2008) 0.86
Sodium chloride, SGK1, and Th17 activation. Pflugers Arch (2014) 0.86
Hepatic mitochondrial dysfunction in manifest and premanifest Huntington disease. Neurology (2013) 0.86
Plasmapheresis for neurological disorders. Expert Rev Neurother (2009) 0.85
Behavioral and neurophysiological evidence for the enhancement of cognitive control under dorsal pallidal deep brain stimulation in Huntington's disease. Brain Struct Funct (2014) 0.85
Constitutive activity of NF-kappa B in myeloid cells drives pathogenicity of monocytes and macrophages during autoimmune neuroinflammation. J Neuroinflammation (2012) 0.85
Spotlight on fumarates. Int MS J (2008) 0.85
Depression in patients with Huntington disease correlates with alterations of the brain stem raphe depicted by transcranial sonography. J Psychiatry Neurosci (2011) 0.85
Complex movement behaviour and progression of Huntington's disease. Neurosci Lett (2007) 0.84
Teaching Video NeuroImages: spinal and bulbar muscular atrophy mimicking essential tremor. Neurology (2012) 0.84
PGC-1alpha downstream transcription factors NRF-1 and TFAM are genetic modifiers of Huntington disease. Mol Neurodegener (2011) 0.84
Central nervous system rather than immune cell-derived BDNF mediates axonal protective effects early in autoimmune demyelination. Acta Neuropathol (2011) 0.83
An exploratory double-blind, randomized clinical trial with selisistat, a SirT1 inhibitor, in patients with Huntington's disease. Br J Clin Pharmacol (2015) 0.83
Better global and cognitive functioning in choreatic versus hypokinetic-rigid Huntington's disease. Mov Disord (2013) 0.82
"Theory of mind" is impaired in Huntington's disease. Mov Disord (2011) 0.82
No association between polymorphisms in the BDNF gene and age at onset in Huntington disease. BMC Med Genet (2006) 0.82
Stimulus-response compatibility in Huntington's disease: a cognitive-neurophysiological analysis. J Neurophysiol (2008) 0.82
Re-expression of a developmentally restricted potassium channel in autoimmune demyelination: Kv1.4 is implicated in oligodendroglial proliferation. Am J Pathol (2007) 0.81
Progressive hepatic mitochondrial dysfunction in premanifest Huntington's disease. Mov Disord (2014) 0.81
Dimethyl fumarate (BG-12) for the treatment of multiple sclerosis. Expert Rev Clin Pharmacol (2013) 0.81
The role of myelin oligodendrocyte glycoprotein in autoimmune demyelination: a target for multiple sclerosis therapy? Expert Opin Ther Targets (2012) 0.81
A randomized, placebo-controlled trial of AFQ056 for the treatment of chorea in Huntington's disease. Mov Disord (2015) 0.80
Alterations in voluntary movement execution in Huntington's disease are related to the dominant motor system: evidence from event-related potentials. Exp Neurol (2008) 0.80
Is the retina affected in Huntington disease? Acta Neuropathol (2005) 0.80
Plasma exchange therapy for steroid-refractory superimposed relapses in secondary progressive multiple sclerosis. J Neurol (2007) 0.80
Neuronal NF-κB ablation does not influence neuro-axonal degeneration in experimental autoimmune demyelination. J Neuroimmunol (2012) 0.80
A novel cognitive-neurophysiological state biomarker in premanifest Huntington's disease validated on longitudinal data. Sci Rep (2013) 0.80
Hepatic mitochondrial dysfunction in Friedreich ataxia. BMC Neurol (2011) 0.78
Polymorphisms in genes encoding leptin, ghrelin and their receptors in German multiple sclerosis patients. Mol Cell Probes (2011) 0.78
Cross sectional PET study of cerebral adenosine A₁ receptors in premanifest and manifest Huntington's disease. Eur J Nucl Med Mol Imaging (2014) 0.78
Advancing therapeutic options in multiple sclerosis with neuroprotective properties. J Neural Transm (Vienna) (2013) 0.78
Visual search as a tool for a quick and reliable assessment of cognitive functions in patients with multiple sclerosis. PLoS One (2013) 0.77
Music perception and movement deterioration in Huntington's disease. PLoS Curr (2011) 0.77
Increase of angiotensin II type 1 receptor auto-antibodies in Huntington's disease. Mol Neurodegener (2014) 0.77
Successful treatment of cerebellar ataxia and tremor in multiple sclerosis with topiramate: a case report. Clin Neuropharmacol (2010) 0.77
Failure to confirm influence of methyltetrahydrofolate reductase (MTHFR) polymorphisms on age at onset of Huntington disease. J Negat Results Biomed (2005) 0.77
MBP-induced experimental autoimmune encephalomyelitis in C57BL/6 mice. J Immunol (2004) 0.77
Evidence for divergent effects of neurodegeneration in Huntington's disease on attentional selection and neural plasticity: implications for excitotoxicity. Brain Struct Funct (2014) 0.77
Age at onset of Huntington disease is not modulated by the R72P variation in TP53 and the R196K variation in the gene coding for the human caspase activated DNase (hCAD). BMC Med Genet (2005) 0.77
Is It Too Early to Predict the Failure of Natalizumab in NMO?-Reply. Arch Neurol (2012) 0.76
CNR1 variation is associated with the age at onset in Huntington disease. Eur J Med Genet (2013) 0.76
Vascular pathology in multiple sclerosis: mind boosting or myth busting? Exp Transl Stroke Med (2011) 0.76
C9ORF72-ALS: P62- and ubiquitin-aggregation pathology in skeletal muscle. Muscle Nerve (2014) 0.76
Dietary Fatty Acids Directly Impact Central Nervous System Autoimmunity via the Small Intestine. Immunity (2016) 0.76
Endogenous ciliary neurotrophic factor modulates anxiety and depressive-like behavior. Behav Brain Res (2012) 0.76
Glutathione S-Transferase Omega 1 variation does not influence age at onset of Huntington's disease. BMC Med Genet (2004) 0.76
Association of age at onset in Huntington disease with functional promoter variations in NPY and NPY2R. J Mol Med (Berl) (2014) 0.76
Functional and structural MRI biomarkers to detect pre-clinical neurodegeneration. Curr Alzheimer Res (2013) 0.76